title: [Allergen immunotherapy - a position paper of the German society for allergology and clinical immunology].
abstract: Mechanisms of allergen immunotherapy (AIT) are complex inducing numerous immunological effects. Successful AIT is most likely based on a functional switch of and tolerance induction in specific T cells downregulating allergic hypersensitivity and inflammation. Subcutaneous AIT for allergic rhinoconjunctivitis and allergic asthma has been successfully assessed in controlled studies with several clinically important allergens (i. e. birch-, grass- and mugwortpollen, dust mites, animal dander) and has shown convincing clinical efficacy. Considered as the only causal treatment besides allergen avoidance at present, AIT can alter the natural course of allergic diseases. Hymenopteravenom hypersensitivity (to bee- and wasp venom) treated with AIT gives the best results compared to AIT with other allergens. AIT is indicated in patients with IgE-mediated sensitizations and corresponding clinical symptoms to allergens, which do not or hardly permit allergen avoidance and which are available as suitable extracts. Decisions about indication and allergen selection should only be made by a physician with certified training or qualified knowledge and skills in allergology. AIT is administered by physicians experienced in this therapy. After addressing tolerability and present status of health the recommended or individually adjusted does is injected and precisely documented, followed by a mandatory waiting period of 30 minutes. Indication for and application of AIT in children are quite similar compared to the treatment of adults. Children tolerate AIT very well and benefit especially from its immunomodulatory effects. Risk factors for and results of unwanted systemic effects can effectively be minimized by training of the staff members involved, adhering to safety standards and immediate emergency treatment. Modified allergens, recombinant proteins and immunomodulatory adjuvants created by basic research are promises for an improved efficacy of AIT with reduced unwanted effects in the future.
authors.affiliation: Arbeitsgruppe Spezifische Immuntherapie der Sektion Immunologie der DGAI, Berlin, Germany. kleine-tebbe@allergie-experten.de
authors.forename: J
authors.initials: J
authors.lastname: Kleine-Tebbe
authors.forename: T
authors.initials: T
authors.lastname: Fuchs
authors.forename: L
authors.initials: L
authors.lastname: Klimek
authors.forename: J
authors.initials: J
authors.lastname: Kühr
authors.forename: U
authors.initials: U
authors.lastname: Lepp
authors.forename: B
authors.initials: B
authors.lastname: Niggemann
authors.forename: J
authors.initials: J
authors.lastname: Rakoski
authors.forename: H
authors.initials: H
authors.lastname: Renz
authors.forename: J
authors.initials: J
authors.lastname: Saloga
authors.forename: J
authors.initials: J
authors.lastname: Simon
mesh_terms: D000485:Allergens; D003888:Desensitization, Immunologic / Q000379:methods*; D005858:Germany; D006801:Humans; D012130:Respiratory Hypersensitivity / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000485:Allergens
vernacular_title: Die spezifische Immuntherapie (Hyposensibilisierung) mit Allergenen1 - Positionspapier der Deutschen Gesellschaft für Allergologie und klinische Immunologieinhaltlich abgestimmt mit dem Arzteverband Deutscher Allergologen -